pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,496
stories
27d
U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown
stat
27d
FDA extends review of Exelixis' colorectal cancer drug candidate
endpoints
28d
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
28d
STAT+: Up and down the ladder: The latest comings and goings
stat
28d
Medicaid will let states use ‘tiers’ to determine medical frailty
stat
28d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
28d
Owkin, Servier ink oncology R&D deal to guide discovery and trial design
fiercebiotech
28d
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
stat
28d
STAT+: Cancer drug shortages keep disrupting patient care
stat
28d
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
28d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
28d
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
28d
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
28d
Boycott launched against American Diabetes Association includes journal
stat
28d
The future of RAS inhibitors
fiercebiotech
28d
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
fiercebiotech
28d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
28d
Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
stat
28d
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
stat
28d
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
28d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
28d
STAT+: Right before midterms, Trump dangles $500 refunds for select ACA enrollees
stat
28d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
28d
Why two promising heart drugs flopped and what’s next
stat
28d
The signal that changes everything: understanding MRD in oncology drug development
fiercebiotech
28d
STAT+: The gifts from pharma companies that keep on giving
stat
29d
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
29d
Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label
endpoints
29d
STAT+: Can AI save rural health care?
stat
29d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
← prev
page 11 of 50
next →
